Skip to content
August 13, 2022

Equity.Guru

Investment information for the new generation

COMPASS

Our Psychedelic Trip Isn’t Over   I don’t know the first thing about psychedelics. Rather, that’s what I would have been saying back in 2020 when the psychedelics sector…
A study was published today in the New England Journal of Medicine which tested COMPASS Pathways’ (CMPS.Q) COMP360 psilocybin. The study is a phase II double-blind, randomized, controlled trial…